DA-1726 vs survodutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

DA-1726

Developed by MetaVia under a licence from Dong-A ST

Phase 1 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in Obesitypeptide
Partial signal

NCT06077864 · Phase 3 · completed

The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.

Next expected readout: December 2026 · NCT07768813 (registry estimate)

Reported efficacy

Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)

Result source: NCT06066515

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDA-1726survodutide
Body weight, % change—Not reported-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515
Weight loss of 5% or more—Not reported82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Weight loss of 10% or more—Not reported68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Waist circumference, change (cm)—Not reported-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377

Body weight, % change

DA-1726
—Not reported
survodutide
-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515

Weight loss of 5% or more

DA-1726
—Not reported
survodutide
82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377

Weight loss of 10% or more

DA-1726
—Not reported
survodutide
68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377

Waist circumference, change (cm)

DA-1726
—Not reported
survodutide
-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

DA-1726: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. DA-1726: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsurvodutide
Dropout rate
—4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
28.6%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.4%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
29.5%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
23.4%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
18.2%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
14.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
16.7%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Serious AEs
7.4%4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
—4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
5.6%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
3.3%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
2.2%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
4.8 mga
nausea 59.3% (placebo 19.5%)
constipation 24.1% (placebo 5.2%)
vomiting 24.1% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
3.6 mg
nausea 63.4% (placebo 19.5%)
vomiting 39.4% (placebo 5.2%)
constipation 31% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
2.4 mg
nausea 65.2% (placebo 19.5%)
vomiting 30.4% (placebo 5.2%)
diarrhoea 22.8% (placebo 10.4%)
NCT04667377 · Phase 2 · registry result, not featured evidence
0.6 mg
nausea 39.1% (placebo 19.5%)
diarrhoea 23.9% (placebo 10.4%)
covid-19 19.6% (placebo 22.1%)
NCT04667377 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

survodutide

Weight -14.94% (n=76) vs -2.82% (n=77) placebo @ 46wk4.8 mg
percent change · % of baseline
NCT04667377 · Phase 2 · registry result, not featured evidence
show 4 more results
-13.22% (n=76) vs -2.82% (n=77) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-12.51% (n=78) vs -2.82% (n=77) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-6.19% (n=76) vs -2.82% (n=77) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-16.6% vs -3.2% placebo @ 76wk
NCT06066515 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 82.8% (n=64) vs 25.9% (n=54) placebo @ 46wk4.8 mg
responder rate · % of participants
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
82% (n=61) vs 25.9% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
81% (n=58) vs 25.9% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
60.7% (n=56) vs 25.9% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight Loss 10% 68.8% (n=64) vs 11.1% (n=54) placebo @ 46wk4.8 mg
responder rate · % of participants
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
65.6% (n=61) vs 11.1% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
65.5% (n=58) vs 11.1% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
33.9% (n=56) vs 11.1% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight Loss 15% 54.7% (n=64) vs 5.6% (n=54) placebo @ 46wk4.8 mg
absolute value · percentage points
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
45.9% (n=61) vs 5.6% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
37.9% (n=58) vs 5.6% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
12.5% (n=56) vs 5.6% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight -18.47 vs -2.68 placebo kg @ 46wk4.8 mg
absolute change · kg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-15.64 vs -2.68 placebo kg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.75 vs -2.68 placebo kg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-7.21 vs -2.68 placebo kg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -16.01 vs -3.96 placebo cm @ 46wk4.8 mg
absolute change · cm
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-14.96 vs -3.96 placebo cm @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.99 vs -3.96 placebo cm @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.32 vs -3.96 placebo cm @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
SBP -8.62 vs -2.46 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.66 vs -2.46 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.08 vs -2.46 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-6.19 vs -2.46 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
DBP -4.8 vs -1.87 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-4.31 vs -1.87 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-4.36 vs -1.87 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-3.31 vs -1.87 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-1726's landscape · survodutide's landscape